VANCOMYCIN HYDROCHLORIDE (vancomycin hydrochloride) by Inpharmus is clinical pharmacology vancomycin is poorly absorbed after oral administration. First approved in 2023.
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
Vancomycin hydrochloride is a bactericidal glycopeptide antibiotic administered intravenously or orally that inhibits bacterial cell-wall biosynthesis and alters cell-membrane permeability. It is a foundational agent for treating serious gram-positive infections including methicillin-resistant Staphylococcus aureus (MRSA), streptococci, and enterococci. The drug has no cross-resistance with other antibiotic classes and demonstrates synergy when combined with aminoglycosides.
Vancomycin is in peak commercial maturity with established market penetration; career opportunities favor experienced managers optimizing market share against multiple generic entrants rather than building new franchise awareness.
CLINICAL PHARMACOLOGY Vancomycin is poorly absorbed after oral administration. In subjects with normal kidney function, multiple intravenous dosing of 1 g of vancomycin (15 mg/kg) infused over 60 minutes produces mean plasma concentrations of approximately 63 mcg/mL immediately after the completion…
Worked on VANCOMYCIN HYDROCHLORIDE at Inpharmus? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on vancomycin offers stability in a mature, essential antibiotic with consistent demand but limited growth ceiling. Career value is optimized for professionals skilled in generic competition, hospital formulary management, and operational excellence rather than innovation or market expansion.